Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H24FN3O3 |
| Molecular Weight | 397.4427 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC(=O)[C@@H](NC(=O)C1=NN(CC2=CC=C(F)C=C2)C3=C1C=CC=C3)C(C)(C)C
InChI
InChIKey=RFCDVEHNYDVCMU-LJQANCHMSA-N
InChI=1S/C22H24FN3O3/c1-22(2,3)19(21(28)29-4)24-20(27)18-16-7-5-6-8-17(16)26(25-18)13-14-9-11-15(23)12-10-14/h5-12,19H,13H2,1-4H3,(H,24,27)/t19-/m1/s1
| Molecular Formula | C22H24FN3O3 |
| Molecular Weight | 397.4427 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:50:25 GMT 2023
by
admin
on
Sat Dec 16 11:50:25 GMT 2023
|
| Record UNII |
544DR70TN4
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WIKIPEDIA |
Designer-drugs-MDMB-FUBINACA
Created by
admin on Sat Dec 16 11:50:25 GMT 2023 , Edited by admin on Sat Dec 16 11:50:25 GMT 2023
|
||
|
DEA NO. |
7020
Created by
admin on Sat Dec 16 11:50:25 GMT 2023 , Edited by admin on Sat Dec 16 11:50:25 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
MDMB-FUBINACA
Created by
admin on Sat Dec 16 11:50:25 GMT 2023 , Edited by admin on Sat Dec 16 11:50:25 GMT 2023
|
PRIMARY | MDMB-FUBINACA (also known as MDMB(N)-Bz-F and FUB-MDMB) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. Although there is no pharmacological information about MDMB-FUBINACA itself, its benzyl analogue (instead of 4-fluorobenzyl) has been reported to be a potent agonist for the CB1 receptor (Ki = 0.14 nM, EC50 = 2.42nM). As of October 2015 MDMB-FUBINACA is a controlled substance in Belarus, Russia, and China. | ||
|
1715016-77-5
Created by
admin on Sat Dec 16 11:50:25 GMT 2023 , Edited by admin on Sat Dec 16 11:50:25 GMT 2023
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
MDMB-FUBINACA
Created by
admin on Sat Dec 16 11:50:25 GMT 2023 , Edited by admin on Sat Dec 16 11:50:25 GMT 2023
|
PRIMARY | MDMB-FUBINACA is a derivative of AB-FUBINACA in which the terminal aminocarbonyl moiety is replaced by a methyl ester group and the isobutyl moiety is substituted with a tert-butyl group. The physiological and toxicological properties of this compound have not been determined. This product is intended for research and forensic applications. | ||
|
DTXSID501010003
Created by
admin on Sat Dec 16 11:50:25 GMT 2023 , Edited by admin on Sat Dec 16 11:50:25 GMT 2023
|
PRIMARY | |||
|
1971007-93-8
Created by
admin on Sat Dec 16 11:50:25 GMT 2023 , Edited by admin on Sat Dec 16 11:50:25 GMT 2023
|
PRIMARY | |||
|
544DR70TN4
Created by
admin on Sat Dec 16 11:50:25 GMT 2023 , Edited by admin on Sat Dec 16 11:50:25 GMT 2023
|
PRIMARY | |||
|
119025665
Created by
admin on Sat Dec 16 11:50:25 GMT 2023 , Edited by admin on Sat Dec 16 11:50:25 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> AGONIST |
Ki
|
||
|
TARGET -> AGONIST |
EC50
|
||
|
TARGET -> AGONIST |
EC50
|
||
|
TARGET -> AGONIST |
Ki
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
